Agilon Health Lowers FY2025 Sales Guidance from $5.850B-$6.025B to $5.810B-$5.830B vs $5.815B Est

Fiscal Year 2025 Guidance

Guidance reflects the full year impact of approximately $150 million from lower-than-expected risk adjustment revenue. Medical margin guidance below includes approximately $70 million of negative prior period development reported year to date, and the full year expected impact from exited markets of $60 million.

Guidance ($M):

	Year Ending December 31, 2025
	Low		High
Medicare Advantage Members1	503,000		506,000
ACO Model Members1,2	113,000		115,000
Total Members Live on Platform1	616,000		621,000
Avg. Medicare Advantage Members	500,000		501,000
Total Revenues	$5,810		$5,830
Medical Margin	($5)		$15
Adjusted EBITDA3	($270)		($245)
Geography Entry Costs4	$32		$30

1.		Membership reflects management's outlook for end of period.
2.		agilon's partnered ACO model entities are not consolidated within its financial results.
3.		Adjusted EBITDA contribution from ACO model entities is expected to be approximately $40-$45 million for fiscal year 2025.
4.		Geography Entry Costs represent the corresponding expense included in the low-end and high-end of management's outlook for Adjusted EBITDA.